Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM

    NEXT STORY
    Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
    PREV STORY
    Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors

    AUSTIN, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology ...

    author_avatar
    NASDAQ Market News

    UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments

    RA’ANANA, Israel and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. ...

    author_avatar
    NASDAQ Market News

    ASTRAZENECA’S FASLODEX MET PRIMARY ENDPOINT IN FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER

    AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg ...

    author_avatar
    NASDAQ Market News